The U.S. Food and Drug Administration has approved Omeros Corporation's (NASDAQ: OMER) YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE